A review on pharmacokinetics, pharmacodynamics and clinical aspects of remdesivir and favipiravir for the treatment of coronavirus disease
The coronavirus disease has spread all over the world. Till now no medicine, vaccine, and any other monoclonal antibodies have been approved for the diagnosis or prevention of COVID-19. In many countries, doctors are considering “repurposing” different approved drugs like interferon-ɑ, lopinavir/ ritonavir, ribavirin, and chloroquine phosphate, etc. to treat COVID-19. Remedesivir (GS-5734) is a prodrug of monophosphoramidate of adenosine analogue. Remedesivir block the viral RNA dependent RNA polymerease (RdRp). Favipiravir (T-705) is also a prodrug and was revealed during evaluating the antiviral activity of chemical agents concerning the influenza virus. This review summarizes the status, mechanisms, preclinical research, and clinical trial progress of remedesivir and favipiravir for the treatment of COVID-19.
Keywords: coronavirus disease, favipiravir, remdesivir, clinical trials, pharmacodynamics
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020.
3. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). Journal of general internal medicine. 2020:1-5.
4. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. American Journal of Roentgenology. 2020:1-7.
5. Mulangu S, Dodd LE, Davey Jr RT, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. New England Journal of Medicine. 2019; 381(24):2293-303.
6. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral research. 2013; 100(2):446-54.
7. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265-9.
8. Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends in immunology. 2020.
9. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research. 2020; 7(1):1-10.
10. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses: Springer; 2015. p. 1-23.
11. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020.
12. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International journal of oral science. 2020; 12(1):1-5.
13. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cellular & molecular immunology. 2020; 17(6):613-20.
14. Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD. SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens. 2020; 9(3):231.
15. Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral research. 2013; 100(3):605-14.
16. Indwiani Astuti Y. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes & Metabolic Syndrome. 2020.
17. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19. New England Journal of Medicine. 2020.
18. Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel medicine and infectious disease. 2020.
19. McCreary EK, Angus DC. Efficacy of Remdesivir in COVID-19. Jama. 2020; 324(11):1041-2.
20. Norrie JD. Remdesivir for COVID-19: challenges of underpowered studies. The Lancet. 2020; 395(10236):1525-7.
21. Baranovich T, Wong S-S, Armstrong J, Marjuki H, Webby RJ, Webster RG, et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. Journal of virology. 2013; 87(7):3741-51.
22. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proceedings of the National Academy of Sciences. 2010; 107(2):882-7.
23. Seneviratne SL, Abeysuriya V, De Mel S, De Zoysa I, Niloofa R. Favipiravir in COVID-19. International Journal of Progressive Sciences and Technologies. 2020; 19(2):143-5.
24. Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Medical Journal Armed Forces India. 2020.
25. Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, et al. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. Journal of Antimicrobial Chemotherapy. 2020; 75(10):2977-80.
26. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016; 531(7594):381-5.
27. Godman B. Combating COVID-19: Lessons learnt particularly among developing countries and the implications. Bangladesh Journal of Medical Science. 2020:103-S 8.
28. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine. 2020; 382(24):2327-36.
29. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrobial agents and chemotherapy. 2011; 55(2):782-7.
30. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & therapeutics. 2020:107512.
31. Madelain V, Nguyen THT, Olivo A, De Lamballerie X, Guedj J, Taburet A-M, et al. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clinical pharmacokinetics. 2016; 55(8):907-23.
32. Yang C-J, Wei Y-J, Chang H-L, Chang P-Y, Tsai C-C, Chen Y-H, et al. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. Journal of Microbiology, Immunology and Infection. 2020.
33. Hashemian SM, Farhadi T, Velayati AA. A review on remdesivir: a possible promising agent for the treatment of COVID-19. Drug design, development and therapy. 2020; 14:3215.
34. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Science. 2020.
35. Hendaus MA. Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19): A simplified summary. Journal of Biomolecular Structure and Dynamics. 2020(just-accepted):1-10.
36. Tchesnokov EP, Gordon CJ, Woolner E, Kocinkova D, Perry JK, Feng JY, et al. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. Journal of Biological Chemistry. 2020; 295(47):16156-65.
37. Tchesnokov EP, Feng JY, Porter DP, Götte M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019; 11(4):326.
38. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral research. 2009; 82(3):95-102.
39. Shannon A, Selisko B, Huchting J, Touret F, Piorkowski G, Fattorini V, et al. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nature communications. 2020; 11(1):1-9.
40. Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019‐nCoV infection. Clinical Pharmacology & Therapeutics. 2020.
41. da Silva MAG. Favipiravir and Coronavirus. future.1:6.
42. Madelain V, Mentré F, Baize S, Anglaret X, Laouénan C, Oestereich L, et al. Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials. CPT: Pharmacometrics & Systems Pharmacology. 2020.
43. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics. 2020;14(1):58-60.
44. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral research. 2018; 153:85-94.
45. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020.
46. Yang X, Liu Y, Liu Y, Yang Q, Wu X, Huang X, et al. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. Expert Review of Clinical Pharmacology. 2020; 13(9):957-75.
47. Wang Y, Zhou F, Zhang D, Zhao J, Du R, Hu Y, et al. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. 2020; 21(1):422.
48. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England). 2020; 395(10236):1569-78.
49. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).